Announcements Trials
Browse Landscape

Phase

Phase NA 5Phase 2 2Phase 1 2Phase 3 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 61Neoplasms 52Neoplasm Metastasis 48Leukemia, Myeloid, Acute 47Colorectal Neoplasms 47Breast Neoplasms 44Prostatic Neoplasms 37Multiple Myeloma 33Ovarian Neoplasms 31Recurrence 27Melanoma 26Pancreatic Neoplasms 25Lymphoma, Non-Hodgkin 25Squamous Cell Carcinoma of Head and Neck 24Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Myelodysplastic Syndromes 22Triple Negative Breast Neoplasms 21Endometrial Neoplasms 21Lung Neoplasms 19Carcinoma, Renal Cell 19Stomach Neoplasms 18Small Cell Lung Carcinoma 18Sarcoma 18Advanced Solid Tumors 18Brain Neoplasms 17Glioblastoma 16Carcinoma, Hepatocellular 16Esophageal Neoplasms 13Solid Tumors 12Lymphoma, B-Cell 12

Interventions

pembrolizumab 1enfortumab vedotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Peripheral Nervous System Diseases × 30 days × Clear all
NCT06405542 2026-06-04

EX-CIPN

University Health Network, Toronto

Phase 1 Active not recruiting
40 enrolled

Peripheral Nervous System Diseases

NCT07484022 2026-06-03

Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer

Generate Biomedicines

Phase 1 Recruiting
37 enrolled
Genitourinary

Carcinoma, Transitional Cell, Peripheral Nervous System Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡